BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31570040)

  • 21. RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis.
    Zeidan AM; Zhu W; Stahl M; Wang R; Huntington SF; Giri S; Podoltsev NA; Gore SD; Ma X; Davidoff AJ
    Leuk Lymphoma; 2019 Dec; 60(13):3181-3187. PubMed ID: 31170846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity.
    Madanat Y; Sekeres MA
    Semin Hematol; 2017 Jul; 54(3):147-153. PubMed ID: 28958288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax.
    Bazinet A; Desikan SP; Li Z; Rodriguez-Sevilla JJ; Venugopal S; Urrutia S; Montalban-Bravo G; Sasaki K; Chien KS; Hammond D; Kanagal-Shamanna R; Ganan-Gomez I; Kadia TM; Borthakur G; DiNardo CD; Daver NG; Jabbour EJ; Ravandi F; Kantarjian H; Garcia-Manero G
    Clin Cancer Res; 2024 Apr; 30(7):1319-1326. PubMed ID: 38300723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure.
    Swaminathan M; Borthakur G; Kadia TM; Ferrajoli A; Alvarado Y; Pemmaraju N; Bodden K; Yearby B; Konopleva M; Khoury J; Bueso-Ramos C; Garcia-Manero G; DiNardo CD
    Leuk Lymphoma; 2019 Sep; 60(9):2207-2213. PubMed ID: 30773968
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts.
    Baek DW; Lee YJ; Kim H; Ahn SY; Ahn JS; Shin HJ; Lee WS; Lee SM; Song IC; Lee HS; Park SW; Choi Y; Cho YY; Bae SH; Kim HJ; Sohn SK; Moon JH
    Ann Hematol; 2018 Dec; 97(12):2309-2317. PubMed ID: 30073392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes.
    Kim Y; Kim IH; Kim HJ; Park S; Lee KH; Kim SJ; Lee JH; Kim DY; Yoon SS; Kim YK; Jang JH; Park SY; Ahn JS; Cheong CW; Lee JH; Cheong JW;
    Int J Hematol; 2014; 99(5):635-43. PubMed ID: 24648120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research.
    Potter VT; Iacobelli S; van Biezen A; Maertens J; Bourhis JH; Passweg JR; Yakhoub-Agha I; Tabrizi R; Bay JO; Chevallier P; Chalandon Y; Huynh A; Cahn JY; Ljungman P; Craddock C; Lenhoff S; Russell NH; Fegueux N; Socié G; Bruno B; Meijer E; Mufti GJ; de Witte T; Robin M; Kröger N
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1615-1620. PubMed ID: 27264633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
    Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
    Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic models in predicting outcomes in myelodysplastic syndromes after hypomethylating agent failure.
    Patel SS; Sekeres MA; Nazha A
    Leuk Lymphoma; 2017 Nov; 58(11):2532-2539. PubMed ID: 28351181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment.
    Geng S; Xu R; Huang X; Li M; Deng C; Lai P; Wang Y; Wu P; Chen X; Weng J; Du X
    Front Immunol; 2022; 13():950134. PubMed ID: 36003379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficacy and safety of venetoclax combined with hypomethylating agents in the treatment of 83 patients with higher-risk myelodysplastic syndromes].
    Liu L; He F; Xu Y; Li T; Li YF; Tang P; Sun L
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):277-283. PubMed ID: 38716600
    [No Abstract]   [Full Text] [Related]  

  • 32. Disease-related costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes.
    Zeidan AM; Wang R; Davidoff AJ; Ma S; Zhao Y; Gore SD; Gross CP; Ma X
    Cancer; 2016 May; 122(10):1598-607. PubMed ID: 26970288
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.
    Takahashi K; Patel K; Bueso-Ramos C; Zhang J; Gumbs C; Jabbour E; Kadia T; Andreff M; Konopleva M; DiNardo C; Daver N; Cortes J; Estrov Z; Futreal A; Kantarjian H; Garcia-Manero G
    Oncotarget; 2016 Mar; 7(12):14172-87. PubMed ID: 26871476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Injectable Hypomethylating Agents for Management of Myelodysplastic Syndromes: Patients' Perspectives on Treatment.
    Zeidan AM; Jayade S; Schmier J; Botteman M; Hassan A; Ruiters D; Hill K; Joshi N
    Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):e185-e198. PubMed ID: 34674983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypomethylating agent based combinations in higher risk myelodysplastic syndrome.
    Chandhok NS; Lewis R; Prebet T
    Leuk Lymphoma; 2020 May; 61(5):1012-1027. PubMed ID: 31814484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents.
    Jabbour E; Faderl S; Sasaki K; Kadia T; Daver N; Pemmaraju N; Patel K; Khoury JD; Bueso-Ramos C; Bohannan Z; Ravandi F; Borthakur G; Verstovsek S; Miller D; Maduike R; Hosing C; Kantarjian HM; Garcia-Manero G
    Cancer; 2017 Feb; 123(4):629-637. PubMed ID: 27741352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. When is the optimal timing for allogeneic transplantation in the case of MDS patients treated with hypomethylating agents?
    Sohn SK; Moon JH
    Expert Rev Hematol; 2013 Aug; 6(4):389-95. PubMed ID: 23991925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?
    Bewersdorf JP; Zeidan AM
    Best Pract Res Clin Haematol; 2021 Mar; 34(1):101245. PubMed ID: 33762100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome.
    Apuri S; Al Ali N; Padron E; Lancet JE; List AF; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):211-214. PubMed ID: 28185797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).
    Lübbert M; Ihorst G; Sander PN; Bogatyreva L; Becker H; Wijermans PW; Suciu S; Bissé E; Claus R
    Br J Haematol; 2017 Feb; 176(4):609-617. PubMed ID: 27905102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.